Filtered By:
Cancer: Breast Cancer
Drug: Arimidex
This page shows you your search results in order of date.
Order by Relevance | Date
Total 143 results found since Jan 2013.
Oral Health Concerns of Female Breast Cancer Survivors on Adjuvant Endocrine Therapy
CONCLUSIONS: Data analysis showed that female breast cancer survivors taking adjuvant endocrine therapy appear more likely to have oral health issues than those not taking such therapy. Improved awareness of these issues is critical. Assessment and management guidelines to address these oral health issues are needed by health care providers.PMID:37678330 | DOI:10.1097/01.NAJ.0000978924.32557.53
Source: The American Journal of Nursing - September 7, 2023 Category: Nursing Authors: So-Hyun Park Shiela M Strauss Source Type: research
The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-Positive HER2-Negative Non-Metastatic Breast Cancer
Conclusion: 5-year letrozole administration could be proposed as first-line therapy for postmenopausal women with HR-positive HER2-negative BC. A considerable subject and long-term follow-up are needed for validation.PMID:37638281 | PMC:PMC10448920 | DOI:10.18502/ijhoscr.v17i1.11713
Source: Cell Research - August 28, 2023 Category: Cytology Authors: Ria Etikasari Tri Murti Andayani Dwi Endarti Kartika Widayati Taroeno-Hariadi Source Type: research
Erratum: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
J Clin Oncol. 2023 Jun 26:JCO2301230. doi: 10.1200/JCO.23.01230. Online ahead of print.NO ABSTRACTPMID:37364217 | DOI:10.1200/JCO.23.01230
Source: Clinical Breast Cancer - June 26, 2023 Category: Cancer & Oncology Source Type: research
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
CONCLUSION: Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.PMID:37079878 | DOI:10.1200/JCO.22.00577
Source: Clinical Breast Cancer - April 20, 2023 Category: Cancer & Oncology Authors: Takuji Iwase Shigehira Saji Kotaro Iijima Kenji Higaki Shoichiro Ohtani Yasuyuki Sato Yasuo Hozumi Yoshie Hasegawa Yasuhiro Yanagita Hiroyuki Takei Maki Tanaka Hideji Masuoka Masahiko Tanabe Chiyomi Egawa Yoshifumi Komoike Toshitaka Nakamura Hiroshi Ohtsu Source Type: research
